Elevai Biosciences highlights past preclinical data on EL-32
The Fly

Elevai Biosciences highlights past preclinical data on EL-32

Elevai Biosciences, a subsidiary of Elevai Labs (ELAB), released past preclinical data from 2022 for EL-32, a pioneering dual-action blocker targeting myostatin and activin-A. Preclinical results generated from our licensing partner in a 2022 study indicated that EL-32 may offer a breakthrough approach to obesity treatment by simultaneously preserving muscle mass and reducing fat mass when used alongside popular weight loss therapies such as GLP-1 receptor agonists. Highlights from the results of these studies include: Enhanced grip strength, with notable, statistically significant increases observed at week 15. Improved motor performance, evidenced by longer, statistically significant rotarod latency durations. Optimized body composition, demonstrated by DEXA scans.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App